◆英語タイトル：Global Breast Reconstruction Market - 2023-2030
	◆商品コード：DTM23FB29 ◆発行会社（リサーチ会社）：DataM Intelligence ◆発行日：2023年1月 ◆ページ数：180 ◆レポート形式：英語 / PDF ◆納品方法：Eメール ◆調査対象地域：グローバル ◆産業分野：医療

The global breast reconstruction market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Breast reconstruction is a surgical process in which an entirely new breast shape or mound is produced. It can be done either following a mastectomy (where the entire breast is removed, occasionally along with the associated lymph nodes and muscles) or following breast conservation (where only parts of the breast are removed). Breast reconstruction is frequently carried out to restore the symmetry of the breasts. The decision to undergo breast reconstruction will depend on many variables, including the patient’s lifestyle, general health, cancer treatment status, and body type.

Market Dynamics

The rise in breast cancer patients and the availability of favorable reimbursement policies, technological advancements and an increase in breast reconstruction procedures are the factors to drive the market in the forecast period.

The increasing prevalence of breast cancer worldwide is expected to drive market growth.

Breast reconstruction is a surgical procedure that restores the breast’s appearance and shape. Women who have previously undergone breast cancer surgeries can get it done. It also promotes using prosthetic implants, autologous tissue, or a combination of both to reconstruct a breast that looks natural. WHO (World Health Organization) estimates that 2.3 million women received breast cancer diagnoses globally in 2020, contributing to 6,85,000 fatalities. Additionally, 7.8 million women diagnosed with breast cancer over the previous five years were still alive in 2020, making it one of the most common cancers worldwide.

Furthermore, 2300 men and about 255,000 women in the United States are diagnosed with breast cancer each year, according to the CDC (Centers for Disease Control and Prevention). The American Society of Plastic Surgeons reports that more than 3.1 million Americans have successfully battled breast cancer. Therefore, it has increased the demand for breast reconstruction worldwide. Thus, from the above factors, the market is expected to drive in the forecast period.

The high cost of breast surgical procedures is expected to hamper the market growth.

Breast reconstruction surgery typically costs between USD 25,000 and USD 50,000, or even more, per breast and between USD 50,000 and USD 100,000 for both breasts. Furthermore, the development of various image detection tests for early stages of breast cancer, such as Mammography, Tomosynthesis, Xeromammography, Galactography, Breast MRI, Scintimammography, Elastography, Breast biopsy, and so on, will reduce the likelihood of undergoing surgical procedures for breast reconstruction, thereby restricting the overall market growth.

COVID-19 Impact Analysis

The coronavirus disease 2019 (COVID-19) pandemic dramatically changed the landscape of plastic surgery across the globe. During the pandemic, hospitals strictly limited the number of surgical cases by following the American College of Surgeons’ COVID-19 surgical triage guidelines. Patients with breast cancer were also referred from outpatient to outpatient plastic surgery clinics for breast reconstruction, and those waiting for breast reconstruction (including autologous tissue reconstruction, implant reconstruction, and nipple-areola reconstruction) at an outpatient plastic surgery clinic who are postponed. For instance, According to the Japan Surgical Society, 56 patients were candidates for breast cancer surgery during this period. The OR restrictions did not affect seventeen breast cancer surgeries scheduled between April 1 and April 19, 2020. From April 20 to June 31, 2020, 39 breast cancer surgeries were scheduled, but 26 (66.7%) were canceled due to a lack of urgency (medium or low). During this time, 41 breast reconstruction surgeries were scheduled. Seventeen more patients had breast reconstruction but did not have surgery scheduled during the time frame. Thus, from the above factors, the market got affected. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Implants segment is expected to hold the largest market share in breast reconstruction market

The implants segment accounted for the largest market share in 2021. The segment is benefiting due to the increasing prevalence of breast cancer cases & breast reconstruction procedures and the increase in demand for silicone & saline breast implants; increasing product launches and FDA approvals are the factors to drive the market segment in the forecast period. For instance, GC Aesthetics, Inc. (GCA) launched its next generation of breast implants, PERLE. PERLE is a highly innovative line of smooth breast implants that includes a proprietary surface technology (BioQ), GCA’s industry-leading gel technology (Emunomic Breast Tissue Dynamic Gel), and an enhanced version of the safety features that have underpinned GCA’s long-term excellent safety record. The new product line offers surgeons and patients an advanced line of smooth implants that benefit from GCA’s over 40 years in the industry, a long-term focus on patient safety and innovation, and exceptional customer service and support. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global breast reconstruction market

North America region accounted for the largest market share in 2021. The increasing prevalence of breast cancer, product launches by the market players, advancement in breast implants, FDA approvals of the products, and rising awareness of breast reconstruction among people are the factors to drive the region’s growth in the forecast period. For instance, according to data published by breast cancer.org, approximately 287,857 new invasive breast cancer cases and 51,400 new non-invasive breast cancer cases will be diagnosed in women in the United States in 2022. In addition, nearly 2,710 new invasive breast cancers were estimated to be diagnosed in men in the same year.

Furthermore, the Breast Reconstruction Awareness Campaign is sponsored by the American Society of Plastic Surgeons (ASPS) and The Plastic Surgery Foundation (PSF), and corporations, institutions, private practices, and individuals financially support it. Its goal is to educate, engage, and empower women to make the best decisions after a breast cancer diagnosis. This includes informing women, family members, caregivers, and the media that the breast cancer loop will remain open until a woman learns about breast reconstruction options. The campaign is multifaceted and includes extensive public communication efforts. Millions of people have been informed about breast reconstruction options following mastectomy through national and local events, programming, and a combination of traditional and new media efforts. Thus, from the above factors, the market is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the breast reconstruction market are Allergan Plc, Sientra, Inc., IDEAL IMPLANT INCORPORATED, Johnson & Johnson, Establishment Labs S.A., GC Aesthetics, Groupe Sebbin SAS, Ideal Implant Incorporated, Laboratoires Arion and Mentor Worldwide LLC

On May 25, 2021, GC Aesthetics launched its next-generation breast implants, PERLE, a highly innovative line of smooth breast implants with a proprietary surface technology.

Allergan Plc:

Overview:

Allergan Plc. is a subsidiary of AbbVie Inc, a specialty pharmaceutical company that creates and markets branded, biosimilar, and over-the-counter (OTC) medications. It offers products in the fields of ophthalmology, dermatology, gastrointestinal, central nervous system, women’s health, urology, and anti-infective therapeutics. The company sells its product to retailers, drug wholesalers, distributors, mail-order businesses, hospitals, clinics, government entities, managed healthcare providers like health maintenance organizations, and other organizations. It has processes across the Americas, Europe, Asia-Pacific, the Middle East, and Africa.

Product Portfolio

Natrelle Breast Implants: Allergan’s Natrelle Silicone-Filled Breast Implants have a silicone outer shell filled with silicone gel. They come in different sizes and have either smooth or textured shells. They are approved for breast augmentation in women age 22 or older and breast reconstruction in women of any age.

The global breast reconstruction market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.